Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
Shanghai Jiao Tong University · Shanghai Chest Hospital · +26 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
237
total citations
- FWCI
- 23.41
- Percentile
- 100%
- References
- 31
Citations per year
Authors
27Topics & keywords
Topics
Keywords
- Biosimilar
- Bevacizumab
- Medicine
- Lung cancer
- Interim
- Tyrosine-kinase inhibitor
- Chemotherapy
- Erlotinib
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.